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Abstract
Background and aims: Cystic Fibrosis (CF) lung disease is characterized by
progressively declining lung function and represents a major factor contributing to
the high morbidity and mortality associated with CF. However, apart from
spirometry, respiratory disease surrogate markers reliably indicating CF lung
disease and the occurrence of pulmonary exacerbations (PEx) are still lacking.
Within this study, we aimed to identify new experimental biomarkers for the
detection of CF lung disease.
Methods: 54 adult and 26 pediatric CF patients were included in the study and
serum concentrations of MMP-1, -2, -8, -9, -13, TIMP-1, TIMP-2, YKL-40,
hyaluronic acid, procollagen III peptide were quantified by ELISA. CF lung disease
was diagnosed by lung function test, PEx was defined based on a clinical scoring
established by Rosenfeld in 2001.
Results: Adults and children with moderate to severe CF lung disease exhibited
significantly increased serum expression of MMP-8, MMP-9, YKL-40 and TIMP-1.
Further, MMP-8, MMP-9 and YKL-40 were significantly increased in adult CF
patients suffering from PEx compared to those without clinical signs of respiratory
exacerbation. MMP-8, MMP-9, YKL-40, and TIMP-1 serum levels were unaffected
by the presence or absence of CF liver disease or pancreatic insufficiency.
Conclusions: MMP-8, MMP-9, and YKL-40 might serve as novel non-invasive
biomarkers of CF lung disease and PEx.
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Introduction
Cystic fibrosis (CF) is the most common autosomal recessive inherited disease
among caucasians with a highly variable genotype and phenotype. Although
generally affecting many organs, lung disease accounts for the majority of
increased morbidity and mortality associated with CF [1]. Clinically, CF lung
disease is characterized by mucostasis, mucus hypersecretion and nonresolving
neutrophilic inflammation. Worsening of respiratory symptoms such as increased
cough or sputum production, or systemic symptoms such as weight loss, anorexia
or fatigue episodically occur in CF patients and are commonly referred to as
pulmonary exacerbations (PEx) [2]. Despite the critical role that both,
progressively declining lung function in CF patients and recurrent episodes of PEx
play in daily clinical routine, no other non-invasive surrogate markers for
existence and progression of CF lung disease apart from spirometry have been
validated or are in wide clinical use. Especially for PEx, neither a standardized
definition nor a reliable laboratory marker defining PEx has entered clinical
routine. Therefore, the diagnosis of PEx is essentially based on clinical evaluation,
and there are considerable variations in identifying and treating PEx, both
between centers and within the same center [3, 4]. Given these considerations it
becomes apparent that a routine marker reliably indicating the existence and/or
worsening of CF lung function and the occurrence of PEx is of clinical need.
Pathophysiologically, CF lung disease is characterized by an abnormal tissue
remodeling and the net accumulation of extracellular matrix (ECM), leading to
subsequent scar formation and ultimately bronchial fibrosis. Mainly from
intensive research on liver and lung fibrosis, a growing understanding of the
pathogenesis of fibrogenesis identified non-invasive quantitative serum fibrosis
markers, which are pathophysiologically derived from extracellular matrix (ECM)
turnover and might directly translate the molecular pathogenesis of fibrogenesis
into clinical application [5, 6, 7, 8]. Further, several of these matrix markers are
also released by neutrophils or induce neutrophil chemokinesis [9, 10, 11, 12].
Based on these considerations we hypothesized that matrix or neutrophil markers
might be associated with impaired lung function and the occurrence of PEx.
Within this study we quantified a large panel of experimental matrix and
neutrophil markers in the serum of CF patients and addressed the questions




This study has been conducted according to the principles expressed in the
Declaration of Helsinki. Written informed consent was obtained from all
participating patients or their parents. The study was approved by the ethics
committee of the medical faculty of the Justus-Liebig-University Giessen
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(Klinikstraße 36, 35392 Giessen, Germany) with the approval no. 75/09. The
diagnosis of CF was established by sweat test and later confirmed by genetic tests
in all subjects. All patients were treated according to European and U.S. guidelines
[13, 14]. Patients were seen in the CF outpatient clinic every 3 months. At each
visit the following parameters were routinely assessed: patient history and physical
examination, sputum and blood samples, and lung function tests including blood
gas analysis (BGA). Serum samples were taken during the office hours of the CF
outpatient clinic (from 8 AM to 2 PM) for the determination of CRP, leukocytes
and liver enzymes. In case of PEx, serum samples were taken before the admission
of antibiotics. Pulmonary function tests were carried out using body plethysmo-
graphy according to established guidelines [15] on a MasterScreen V4.6 (VIASYS
Healthcare GmbH, Hoechberg, Germany). All values were normalized to weight
adapted normal values with respect to the individual body-mass-index (BMI). To
address whether matrix and neutrophil markers can serve as biomarkers of CF
lung disease, we assessed their serum expression in CF patients with a forced
expiratory volume in one second (FEV1) below and above 80%, with a vital
capacity (VC) of below and above 80%, and with a ratio between FEV1 and VC
below and above 70% (FEV1/VC), all of which serve as established indicators of
CF lung disease and have been the primary outcome in many clinical trials
[13, 16, 17, 18]. For the purpose of statistical analysis, the following terminology of
CF lung disease was utilized: (i) patients with a decline of FEV1 and VC below
80% and a FEV1/VC below 70%: moderate to severe CF lung disease, (ii) patients
with a FEV1 and VC$80% and a FEV1/VC ratio $70%: mild CF lung disease.
Patients were instructed to report to the clinic immediately whenever symptoms
suggestive of acute pulmonary exacerbation (PEx) appeared. PEx was defined
based on the PEx score established by Rosenfeld in 2001 [19]. The PEx score
consists of six common clinical findings each weighted by a certain coefficient (in
brackets): decreased exercise tolerance (1.8), increased cough (1.5), increased
cough/sputum congestion (1.5), school or work absenteeism (1.6), increased
adventitial sound on lung examination (1.2), and decreased appetite (1.1) [19].
Pulmonary exacerbation was presumed when the PEx score exceeded the critical
value of 2.6. If senior CF specialists considered the exacerbation severe enough
systemic antibiotic therapy was instituted. Choice of antibiotic therapy was based
on the results of the most recent sputum culture. Cystic fibrosis liver disease
(CFLD) was diagnosed according to recent guidelines [20] if at least two of the
following conditions on at least two consecutive examinations spanning a one-
year period were present: (i) Hepatomegaly (liver span.2 cm below the costal
margin on the medioclavicular line) confirmed by ultrasound, (ii) two abnormal
serum liver enzyme levels (ALT, AST, cGT. ULN), (iii) ultrasound abnormalities
other than hepatomegaly (increased, heterogeneous echogenicity, nodularity,
irregular margins).
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Routine laboratory tests and determination of experimental matrix
and neutrophil markers
All patients underwent routine haematological and biochemical investigations on
the day of quantification of serum biomarkers. The following arrays and assays
were used to quantify serum levels of experimental biomarkers: Serum MMP-1, -
2, -8, -9, and -13 protein levels were measured using the Fluorokine MAP
multiplex human MMP panel (R&D Systems, Minneapolis, USA). TIMP-1,
TIMP-2, C-terminal procollagen III peptide (PIIIP), hyaluronic acid (HA) and
YKL-40 were determined using commercially available kits with a serum dilution
of 1:200 for TIMP-1 and TIMP-2, 1:13 for PIIIP, 1:1 for HA and undiluted for
YKL-40 (MMP-9: Cat.No. DY911; TIMP-1: Cat.No. DY970; TIMP-2: Cat.No.
DY971, all R&D Systems, Weinheim, Germany; PIIIP: Cat.No. E3087Hu, YKL-40:
Cat.No. 8020, both from Quidel, San Diego, USA; HA: Cat.No. TE1017,
Osteomedical, Bu¨nde, Germany).
Statistical analysis
Statistical analysis was performed with SPSS 21.0 (SPSS Inc, Chicago, Ill). Normal
distribution of the data was tested using the Kolmogorov–Smirnov test and
visualization of histograms. Failing to meet criteria for normal distribution, were
analyzed using non-parametric tests. Expression of serum markers is shown in
Box-and-Whisker Plots. The upper and lower hinges of the box represent the 75th
and 25th percentile, respectively. The line indicates the median value; error bars
represent the minimum and maximum. Values deviating from the box by 1.5- to
3-fold interquartile range were defined as outliers (o). Significant differences are
pointed out (*p,0.05, **p,0.01).
Results
Patient characteristics
Clinical and demographic data of the 54 adult and 26 pediatric CF patients that
were included in the study are presented in Table 1 and 2, respectively.
Lung function and biomarker expression
When stratifying our adult patient cohort according to previously defined
established parameters of CF lung disease [13, 16, 17, 18], a total of 20 adults with
CF exhibited a decline of FEV1 and VC below 80% and a FEV1/VC ratio below
70%, all indicative of moderate to severe CF lung disease, and we observed a
robust and significant increase of MMP-8 and YKL-40 in these patients with
moderate to severe CF lung disease compared to those without a relevant decline
in lung function or only mild CF lung disease (as indicated by a FEV1 and VC
above 80% or a FEV1/VC ratio above 70%) (Figs. 1 and 2). Further, serum
expression of MMP-9 and TIMP-1 were significantly increased in CF patients with
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Table 1. Demographic and clinical data of the adult CF patient cohort.
Adult CF patients (n 554)
Mild CF lung disease
(n 534)
Moderate to severe CF
lung
disease (n 520) Significance
Demographic and clinical data
Men (n) 21 10 p 50.403
Women (n) 13 10
Age (y)
mean (median) ¡ SD 32.2 (31)¡8.8 30.9 (30) ¡7 p 50.647
BMI (kg/m2)
mean (median) ¡ SD 21.2 (21)¡2.5 20.2 (20) ¡2.7 p 50.119
CFLD (n)
no CFLD 16 6 p 50.222
CFLD 18 14
%FEV1
mean (median) ¡ SD 73 (73) ¡19 40 (39) ¡13 p,0.001
%VC
mean (median) ¡ SD 86 (88) ¡16 69 (73) ¡17 p 50.003
Biochemistry
Hemoglobin (g/dL)
mean (median) ¡ SD 14.1 (14.4) ¡2.1 14.2 (14.5) ¡1.7 p 50.971
range 8.5–17.1 10.5–16.9
Platelet count (G/L)
mean (median) ¡ SD 282 (282) ¡103 295 (282) ¡99 p 50.837
range 132514 1132541
Alanine aminotransferase (U/L
mean (median) ¡ SD 27 (25) ¡16 24 (21) ¡12 p 50.622
range 7283 10255
c-glutamyl transpeptidase (U/L)
mean (median) ¡ SD 32 (19) ¡31 35 (19) ¡38 p 50.762
range 92114 62137
Bilirubin (mg/dL)
mean (median) ¡ SD 1.4 (0.9) ¡1.9 0.7 (0.6) ¡0.5 p 50.511
range 0.1–7 0.2–1.8
Albumin (g/dL)
mean (median) ¡ SD 4.3 (4.4) ¡0.38 4.2 (4.2) ¡0.39 p 50.437
range 3.4–4.9 3.3–4.6
Prothrombin time (%)
Mean (median) ¡ SD 89 (97) ¡22 91 (90) ¡13 p 50.625
range 212112 722116
CrP (G/L)
mean (median) ¡ SD 17 (7) ¡48 20 (10) ¡31 p 50.163
range 02285 02135
doi:10.1371/journal.pone.0115847.t001
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Table 2. Demographic and clinical data of the pediatric CF patient cohort.
Pediatric CF patients (n 526)
Mild CF lung
disease (n 519)
Moderate to severe CF
lung disease (n 57) Significance
Demographic and clinical data
Men (n) 7 6 p 50.063
Women (n) 12 1
Age (y)
mean (median) ¡ SD 11.5 (13)¡5.5 15 (16) ¡2.9 p 50.025
BMI (kg/m2)
mean (median) ¡ SD 20.22 (20.5) ¡1.1 21.34 (21.7) ¡1.1 p 50.041
CFLD (n)
no CFLD 11 5 p 50.611
CFLD 8 2
%FEV1
mean (median) ¡ SD 91 (94) ¡15 61 (65) ¡23 p 50.004
%VC
mean (median) ¡ SD 87 (89) ¡19 79 (76) ¡29 p 50.657
Biochemistry
Hemoglobin (g/dL)
mean (median) ¡ SD 13.8 (13.8) ¡0.9 14.2 (14.2) ¡1.2 p 50.364
range 12.4–15.6 12.5–16
Platelet count (G/L)
mean (median) ¡ SD 329 (326) ¡64 346 (332) ¡80 p 50.651
range 2172418 2172484
Alanine aminotransferase (U/L
mean (median) ¡ SD 36 (30) ¡19 26 (24) ¡15 p 50.156
range 17285 12254
c-glutamyl transpeptidase (U/L)
mean (median) ¡ SD 22 (16) ¡24 39 (18) ¡45 p 50.231
range 72115 132138
Bilirubin (mg/dL)
mean (median) ¡ SD 0.5 (0.3) ¡0.4 0.3 (0.3) ¡0.1 p 50.971
range 0.2–1.8 0.1–0.4
Albumin (g/dL)
mean (median) ¡ SD 4.4 (4.4) ¡0.2 4.4 (4.5) ¡0.4 p 50.974
range 4.1–4.7 3.9–4.8
Prothrombin time (%)
Mean (median) ¡ SD 87 (90) ¡11 86 (84) ¡7 p 50.828
range 68–106 76–95
CrP (G/L)
mean (median) ¡ SD 1 (0) ¡3 8 (8) ¡6 p 50.004
range 0212 0217
BMI SDS, Body Mass Index Standard Deviations Score.
doi:10.1371/journal.pone.0115847.t002
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a declined VC (MMP-9 and TIMP-1) and FEV1 (TIMP-1) or a declined FEV1/VC
ratio (MMP-9) (Figs. 1 and 2). In contrast, serum expression of MMP-1, -2, -13,
TIMP-2, hyaluronic acid (HA), and procollagen III peptide (PIIIP) was
unchanged between CF patients with a FEV1 (S1 Table) or VC (S2 Table) below
and above 80%, or a ratio of FEV1/VC (S3 Table) above and below 70%.
Liver and pancreas represent two other organ systems that are, apart from the
lung, frequently affected by CF and thus might act as potential confounders of the
observed up-regulation of MMP-8, MMP-9, YKL-40 and TIMP-1 in CF lung
disease. Hence, we also assessed biomarker serum expression in patients with and
without CF associated liver disease (CFLD) as diagnosed according to recent
established guidelines [20], Importantly, none of the biomarkers differed between
CF patients with and without CFLD (Table 3). Regarding pancreatic insuffi-
ciency, only 3 patients of the adult CF cohort had no pancreatic insufficiency,
while 51 patients were pancreatic insufficient. In these exploratory analyses, none
of the biomarkers exhibited significant differences between adults with and
without pancreatic insufficiency either. Further, CF patients stratified according to
lung function into those with mild or moderate to severe CF lung disease did not
exhibit any differences in laboratory or clinical markers indicative of CF liver
disease (Table 1). Together, these data indicate that the observed increased
expression of MMP-8, MMP-9, YKL-40, and TIMP-1 occur indeed relatively
Fig. 1. Serum expression of MMP-8 and MMP-9 in adult CF patients with CF lung disease. In adult CF patients serum MMP-8 levels were consistently
increased in patients with moderate to severe CF lung disease, as assessed by declined %FEV1 and %VC below 80% and a declined ratio of FEV1/VC
below 70%, compared to those with mild CF lung disease (FEV1&VC: $80%; FEV1/VC ratio: $70%). Serum MMP-9 was also significantly increased in CF
patients with decreased %VC and decreased FEV1/VC. Upper and lower hinge: 75th and 25th percentile, respectively; Line: median value; Error bars:
minimum and maximum (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0115847.g001
Expression of Neutrophil Markers in CF Lung Disease
PLOS ONE | DOI:10.1371/journal.pone.0115847 December 29, 2014 7 / 18
specific for the existence of CF lung disease without being affected by pancreas
and liver disease as other major manifestations of CF.
To further substantiate the association of the aforementioned biomarkers with
CF lung disease, we turned our attention to a cohort of 26 pediatric CF patients,
of which clinical and demographic data are summarized in Table 2. In these CF
children, we also assessed serum expression of the whole panel of ECM markers
and similarly to our observations in adult CF patients, when CF children were
stratified according to FEV1 and VC below or above 80% or a ratio of FEV1/VC
below or above 70%, we found significantly increased serum levels of MMP-8 and
MMP-9 (Fig. 3) with each of these stratification indicative of moderate to severe
CF lung disease. Further, YKL-40, and TIMP-1 were significantly increased in CF
children with reduced VC (YKL-40) or FEV/VC ratio (TIMP-1) (Fig. 4). Similar
to our observations in adults, serum expression of MMP-1, -2, -13, TIMP-2, HA,
and PIIIP was unchanged between pediatric CF patients with a FEV1 (S4 Table)
or VC (S5 Table) below and above 80%, or a ratio of FEV1/VC (S6 Table) above
and below 70%.
Similar to the analyses performed in adults, we then analyzed biomarker
expression in CF children in those with and without CFLD and analyzed
biomarker expression in these subgroups. Consistent with our observations in
adults, CF children with lung disease exhibited a significant decrease in
Fig. 2. Serum expression of YKL-40 and TIMP-1 in adult CF patients with CF lung disease. In adult CF patients serum YKL-40 levels were consistently
increased in patients with moderate to severe CF lung disease, as assessed by declined %FEV1 and %VC below 80% and a declined ratio of FEV1/VC
below 70%, compared to those with mild CF lung disease (FEV1&VC: $80%; FEV1/VC ratio: $70%). Serum TIMP-1 was also significantly increased in
adult CF patients with decreased %VC and decreased %FEV1. Upper and lower hinge: 75th and 25th percentile, respectively; Line: median value; Error
bars: minimum and maximum. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0115847.g002
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parameters of pulmonary function and a slight increase in CrP levels whereas
other laboratory or clinical markers were unchanged (Table 2) between children
with and without CF lung disease. Importantly, serum biomarker expression was
unaltered in CF children with and without CFLD (Table 4). Regarding pancreatic
insufficiency, only 2 children with CF were pancreatic sufficient, thereby only
allowing exploratory analyses. However, in these exploratory analyses, none of the
analyzed biomarkers differed between CF children with and without pancreatic
insufficiency. Thus these results indicate that serum expression of MMP-8, MMP-
9, YKL-40, and TIMP-1 are also associated with declined lung function in CF
children and that this association is indeed rather specific to lung disease and not
affected by CFLD or pancreatic insufficiency, although the latter analysis has only
exploratory character.
Table 3. Serum expression of matrix and neutrophil markers in adult CF patients without (n 522) and with (n 532) CFLD.
without CFLD with CFLD Significance
YKL-40 (ng/mL)
Mean ¡ SD 85.2¡38.5 105.2¡62.8 p 50.360
Median (range) 83.6 (31.2–172.8) 81.3 (21.4–275)
MMP-1 (ng/mL)
Mean ¡ SD 1593¡925 1446¡795 p 50.660
Median (range) 1430 (450–4160) 1285 (410–3430)
MMP-2 (ng/mL)
Mean ¡ SD 12.44¡2.6 13.09¡2.4 p 50.379
Median (range) 12.76 (6.7–18.6) 13.14 (8.02–18.45)
MMP-8 (ng/mL)
Mean ¡ SD 54.9¡45.2 59.7¡43.3 p 50.771
Median (range) 43.3 (11.3–178.1) 49.2 (2.3–156.1)
MMP-9 (ng/mL)
Mean ¡ SD 1896¡692 2057¡877 p 50.400
Median (range) 1690 (85–3280) 2220 (290–3610)
MMP-13 (ng/mL)
Mean ¡ SD 19.27¡15.34 49.26¡151.26 p 50.298
Median (range) 11.93 (1.6–41) 4.96 (0–651)
TIMP-1(ng/mL)
Mean ¡ SD 59.3¡30.4 66.9¡23.1 p 50.149
Median (range) 53.5 (21.1–161.3) 63.2 (27.9–128.7)
TIMP-2 (pg/mL)
Mean ¡ SD 123.33¡18.17 129.94¡30.1 p 50.606
Median (range) 120.72 (89.2–149) 125.7 (80.8–211.1)
HA (ng/mL)
Mean ¡ SD 22.35¡15.36 32.72¡25.96 p 50.143
Median (range) 21.99 (0.79–50.3) 28.96 (7.2–127.5)
PIIIP (ng/mL)
Mean ¡ SD 14.85¡29.45 14.32¡23.6 p 50.898
Median (range) 5.02 (1.2–136.1) 4.88 (0–122)
doi:10.1371/journal.pone.0115847.t003
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Finally, to further substantiate these associations of MMP-8, -9, YKL-40, and
TIMP-1 expression with declined pulmonary function, we then hypothesized that
CF patients with a pulmonary exacerbation (PEx) might also exhibit an increase
of the aforementioned biomarkers. Of the 55 adult CF patients, 16 (29.1%)
suffered from PEx and parameters of lung function were significantly impaired in
patients suffering from PEx compared to CF patients without clinical signs of
exacerbation. In these analyses, serum expression of YKL-40, MMP-8, MMP-9,
and TIMP-1 were increased in CF patients with PEx compared to those without
clinical signs of pulmonary exacerbation (Fig. 5). Importantly, all of the other
biomarkers analyzed (MMP-1, MMP-2, MMP-13, TIMP-2, HA, PIIIP) were
unaltered between CF patients with PEx and those without, thereby indicating
that ECM markers are not generally up-regulated in CF patients with pulmonary
exacerbation and declined lung function, but rather occurs selectively on the level
of individual markers.
Discussion
Progressively declining lung function in CF patients represents the most common
cause of CF associated mortality [21, 22, 23]. Further, CF lung disease is
characterized by increased bacterial endobronchial burden, repetitive cycles of
Fig. 3. Serum expression of MMP-8 and MMP-9 in pediatric CF patients with CF lung disease. Serum levels of both, MMP-8 and MMP-9 in children with
moderate to severe CF lung disease, as assessed by declined %FEV1 and %VC below 80% and a declined ratio of FEV1/VC below 70%, compared to
children with mild CF lung disease (FEV1&VC: $80%; FEV1/VC ratio: $70%). Upper and lower hinge: 75th and 25th percentile, respectively; Line: median
value; Error bars: minimum and maximum. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0115847.g003
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non-resolving neutrophilic inflammation with impaired antibacterial killing and
subsequent proteolytic destruction of pulmonary tissue [24]. Despite the central
role that CF lung disease and recurrent episodes of pulmonary exacerbations play
in clinical care of CF patients, surprisingly little non-invasive diagnostics apart
from spirometry are available to adequately and routinely diagnose, monitor and
follow-up CF lung disease. So far, about eighty experimental biomarkers,
including inflammatory cytokines, acute phase reactants, and markers of oxidative
stress, have been evaluated for the diagnosis of CF lung disease and pulmonary
exacerbations [25]. Among these, especially neutrophil elastase within the sputum
has been identified as a promising candidate marker that correlates with declined
lung function and pulmonary inflammation in CF [26, 27, 28]. Further, it has been
shown that neutrophil elastase exhibits profound immunologic effects within the
lung such as activation of IL-8 [29], or cleavage of the matrix remodeling enzymes
MMP-9 and TIMP-1 [30].
Based on this knowledge, we hypothesized that experimental matrix and
neutrophil markers, determined within the serum, might act as novel non-
invasive biomarkers of CF lung disease. As surrogate makers of CF lung disease,
we used FEV1, VC and the FEV1/VC ratio, all of which are established indicators
of CF lung disease and have been the primary outcome in many clinical trials.
Using this approach, we found that serum expression of MMP-8, MMP-9, YKL-
40, and TIMP-1 were significantly increased in adult and pediatric patients with
Fig. 4. Serum expression of YKL-40 and TIMP-1 in pediatric CF patients with CF lung disease. Serum levels of YKL-40 were significantly increased in
children with reduced %VC and increased by trend in children with a reduced FEV1/VC ratio. TIMP-1 was increased in CF children with a reduced FEV1/VC
ratio below 70% compared to those with a ratio above 70%. Upper and lower hinge: 75th and 25th percentile, respectively; Line: median value; Error bars:
minimum and maximum. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0115847.g004
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moderate to severe CF lung disease compared to those without without a relevant
decline in lung function or only mild CF lung disease. Importantly, expression of
these markers was unaffected in the presence or absence of liver or pancreas
disease, as shown in sub-analyses in this study. Thus, our results indicate that the
aforementioned markers are rather specific for CF lung disease and hence might
represent novel and non-invasive biomarkers of CF lung disease.
The family of Matrix Metalloproteinases (MMPs) consists of so far 28 identified
proteolytic enzymes, which hold the potential to degrade virtually all components
of the extracellular matrix and together with their specific inhibitors, the tissue
inhibitors of metalloproteinases (TIMPs), are the main mediators of turnover and
homeostasis of the ECM. Previous studies already have shown that deregulated
Table 4. Serum expression of matrix and neutrophil markers in pediatric CF patients without (n 516) and with (n 510) CFLD.
without CFLD with CFLD Significance
YKL-40 (ng/mL)
Mean ¡ SD 52.8¡23.2 69.1¡40.8 p 50.412
Median (range) 50.4 (22.1–114.6) 59.2 (22–157)
MMP-1 (ng/mL)
Mean ¡ SD 1074¡787 1381¡992 p 50.521
Median (range) 800 (350–3460) 1270 (240–3430)
MMP-2 (ng/mL)
Mean ¡ SD 17.6¡3.8 19.7¡4.97 p 50.238
Median (range) 16.9 (12.6–26.8) 19.7 (12.91–28.34)
MMP-8 (ng/mL)
Mean ¡ SD 45.4¡46.2 21.6¡15.5 p 50.159
Median (range) 27.1 (0–189.7) 19.3 (0–54.6)
MMP-9 (ng/mL)
Mean ¡ SD 1537¡863 1201¡879 p 50.204
Median (range) 1275 (280–3280) 830 (340–3270)
MMP-13 (ng/mL)
Mean ¡ SD 62.59¡58.4 71.8¡40.4 p 50.317
Median (range) 49.3 (0–249) 70.7 (0.2–131.7)
TIMP-1(ng/mL)
Mean ¡ SD 61.2¡8.8 61.1¡19.8 p 51.00
Median (range) 61.7 (41.8–72.9) 58.4 (27.6–89.5)
TIMP-2 (pg/mL)
Mean ¡ SD 131.4¡25.3 150.4¡23.2 p 50.084
Median (range) 133.5 (94.7–178) 149 (125.6–210)
HA (ng/mL)
Mean ¡ SD 19.2¡10.4 22.9¡16.3 p 50.642
Median (range) 17.5 (0–40.3) 26.6 (0–45.1)
PIIIP (ng/mL)
Mean ¡ SD 9.1¡12.2 21¡39.1 p 50.707
Median (range) 4.3 (2–50.5) 8.2 (0–136.1)
doi:10.1371/journal.pone.0115847.t004
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MMP activity either leads to exaggerated ECM turnover, impaired repair, and scar
formation or to ECM accumulation with subsequent tissue fibrosis in chronic
lung diseases [31, 32, 33]. In addition to that, accumulating evidence suggests that
MMPs indeed play a central role in the pathophysiology of lung tissue remodeling
associated with CF. In this regard, several studies have documented enhanced
MMP levels in BAL fluid or sputum of CF patients [34, 35, 36, 37] and especially
MMP-9 has been shown to be associated with declined lung function and airway
inflammation in CF [34, 35]. Further, basic research corroborates the etiologic
role of MMP-8 and MMP-9 for pulmonary inflammation in CF [38, 39] and it
was demonstrated that peroxisome proliferator-activated receptor (PPARc)
agonists can inhibit the inflammatory response in CF cell lines and CF mice at
least in part by the attenuation of NF-kB-driven processes such as MMP-9
production [38]. Strikingly, Gaggar and co-workers found that MMP-8 and
MMP-9 are involved in the production of a strong ECM-derived neutrophil
chemoattractant, and therefore potentially contribute to neutrophil influx and
airway damage in CF patients [39]. Within this study, we now show that both,
MMP-8 and MMP-9 are increased in the serum of CF patients with CF lung
disease and our results thus indicate that the previously observed increased MMP
expression in bronchial tree of individuals with CF [34, 35, 36, 37] seems to be
reflected in the blood compartment, revealing a potential role of MMPs as non-
invasive and novel biomarkers of CF lung disease. Further, we observed robust
and significantly increased serum levels of the chitinase-like protein YKL-40 in
Fig. 5. Serum expression of MMP-8, MMP-9, YKL-40, and TIMP-1 in adult CF patients with pulmonary
exacerbation. Serum levels of YKL-40 were highly significant increased in adult CF patients suffering from
pulmonary exacerbation (PEx) compared to those without PEx. Further, MMP-8, MMP-9, and TIMP-1 were
significantly increased in serum from adults with PEx compared to CF patients without respiratory
exacerbation. Upper and lower hinge: 75th and 25th percentile, respectively; Line: median value; Error bars:
minimum and maximum. (*p,0.05, **p,0.01).
doi:10.1371/journal.pone.0115847.g005
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adults and children with CF lung disease. Importantly, a recent study was able to
demonstrate that YKL-40 levels are increased in sputum and serum of CF patients
compared to healthy control individuals [40], and in both CF patients and
bENaC-Tg mice, a murine model mirroring CF lung disease [41], airway levels of
YKL-40 and its murine analogue BRP-39 airway levels correlated with the severity
of pulmonary obstruction [40]. Further, two YKL-40 SNPs were found to
modulate age-adjusted lung function in CF patients [40]. Besides its role in CF, it
also has been shown that YKL-40 serum levels are increased in patients with severe
asthma [42] and chronic obstructive pulmonary disease (COPD) [43], both of
which are also characterized by neutrophilic inflammation. Together with these
data, our findings suggest that YKL-40 might indeed represent a novel biomarker
of CF lung disease.
Importantly, in order to further substantiate our findings of increased MMP-8,
MMP-9, and YKL-40 expression in CF lung disease, we analyzed their expression
in adult CF patients currently suffering from PEx. In these analyses, we found that
PEx patients exhibit even higher levels of MMP-8, MMP-9, and YKL-40 compared
to CF patients without clinical signs of pulmonary exacerbation. These findings
have important implications. Firstly, until now neither a standardized definition
of PEx has been published nor accepted and as a result the presence of an
exacerbation remains essentially a clinical diagnosis [16, 44]. Thus, routine
markers reliably indicating the occurrence of pulmonary exacerbations in CF are
of clinical need, and our results indicate that MMP-8, MMP-9, and YKL-40 might
indeed be utilized as novel serum markers facilitating the diagnosis of PEx.
Secondly, from the results of the current study, the question about the cell types
responsible for the increased MMP and YKL-40 production arises, and although
we were not able to allocate the MMP and YKL-40 secretion to a certain cell type,
it can be speculated that the observed increases in PEx reflect the extent of
neutrophilic airway inflammation. Although this aspect clearly is speculative in its
nature, this view is supported by the notion that neutrophils represent a main
source of MMP-production, especially of MMP-8 (5neutrophilic collagenase)
and MMP-9, and have also been shown to store YKL-40 within their secretory
granula [24]. However, to further substantiate this hypothesis, further studies are
needed in which biomarker levels in serum and sputum are assessed
simultaneously along with identification of the main cellular sources of these on
serum, sputum, and tissue level.
Possible limitations of this study should also be addressed, one of which is the
impossibility to directly relate the increased serological biomarker expression to
pulmonary tissue as the origin of these biomarkers. Especially members of the
MMP family and YKL-40 have also been shown to be associated with other
systemic diseases such as cardiovascular disease or diabetes [45, 46, 47, 48, 49]. On
the other hand, as already discussed above, members of the MMP family and
YKL-40 have been shown to be increased in the airways of CF patients
[10, 34, 35, 36, 37, 40, 50] and thus, it might well be speculated that the observed
increased serum levels are indeed derived from the bronchial tree of CF patients.
As a further limitation, the number of patients without pancreatic insufficiency
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was rather small. This problem results from the natural course of disease, with 80
to 90% of all CF patients being pancreatic insufficient [51, 52] and an onset of
pancreatic insufficiency in very early stages of life [51], thus making it challenging
to recruit large number of CF patients without pancreatic insufficiency. Hence,
although the subgroup analysis of biomarker expression with regard to the
presence or absence of pancreatic insufficiency presented in this study is
exploratory in its nature, the results do support the concept that the up-regulation
of individual biomarkers in the serum of CF patients is associated with declined
pulmonary function, but not with the presence or absence of CFLD or PI.
In summary, we have shown that adult and pediatric CF patients with moderate
to severe CF lung disease exhibit increased serum levels of MMP-8, MMP-9, and
YKL-40 and that this association occurs rather organ specific as is not influenced
by the co-existence or absence of CFLD. Further, CF patients suffering from
pulmonary exacerbation exhibit further increased serum levels of these
biomarkers. Hence, MMP-8, MMP-9, and YKL-40 might represent novel
serological markers of CF lung disease and pulmonary exacerbations.
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